Cinergen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Cinergen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Cinergen Today - Breaking & Trending Today

Cinergen: Najib Babul Discusses the Benefits and Limitations of the 505(B)(2) Regulatory Pathway For Drug Approval


(2)
CLARK COUNTY, NV / ACCESSWIRE / January 7, 2021 / Hardly a week goes by without a pharmaceutical company expressing the desire to reap the benefits of developing a drug using the 505(b)(2) regulatory pathway. What are 505(b)(2) new drug applications (NDAs) and do they really provide a meaningful advantage to pharmaceutical companies? Dr. Najib Babul, an experienced drug development and regulatory affairs consultant discusses the benefits and limitations of this drug approval pathway.
The term 505(b)(2) is derived from Section 505 of the Federal Food, Drug and Cosmetic Act, as amended by the Drug Price Competition and Patent Term Restoration Act of 1984. The latter is informally known as the Hatch-Waxman Act, so named after its legislative sponsors, Representative Henry Waxman of California and Senator Orrin Hatch of Utah. Section 505(b)(2) refers to NDAs for whom some of the information required for approval comes from sources other than the applicant, or for which ....

New York , United States , United Kingdom , Kostenloser Wertpapierhandel , Henry Waxman , University Of British Columbia , University Of New York , European Parliament , Pharmaceuticals For Children , California Institute Of Advanced Management , Najib Babul , Federal Food , Cosmetic Act , Drug Price Competition , Patent Term Restoration Act , Hatch Waxman Act , Representative Henry Waxman , Senator Orrin Hatch , Best Pharmaceuticals , Children Act , British Columbia , State University , California Institute , Clinical Pharmacology , Clinical Oncology , புதியது யார்க் ,

Cinergen: Najib Babul Discusses Erythropoietic Protoporphyria for a Severe Photodermatosis


Cinergen: Najib Babul Discusses Erythropoietic Protoporphyria for a Severe Photodermatosis
CLARK COUNTY, NV / ACCESSWIRE / January 7, 2021 / Erythropoietic protoporphyria (EPP) is a devastating lifelong disorder characterized by dermal photosensitivity with only one recently approved treatment and very few evidence-based clinical management tools. Dr. Najib Babul, an experienced drug development and regulatory affairs consultant discusses this serious debilitating condition.
EPP is a rare inherited disorder of heme biosynthesis characterized by dermal photosensitivity secondary to a partial deficiency of ferrochelatase. In a phenotypically similar X-linked protoporphyria (XLP), there is overactivity of the heme biosynthesis enzyme, erythropoietic aminolevulinate synthase (ALAS2). Both EPP and XLP result in the accumulation of the photosensitizer protoporphyrin IX (PPIX) in erythrocytes, plasma, skin and liver. The accumulated PPIX is activated by sun exposure, thus generat ....

New York , United States , United Kingdom , Jasmin Barman Aks , Kostenloser Wertpapierhandel , Tanabe Pharma , Victor Hruby , Robert Dorr , Mac Hadley , Clinuvel Pharmaceuticals , University Of British Columbia , University Of New York , Uk National Institute For Health , University Of Arizona , California Institute Of Advanced Management , Najib Babul , N Acetyl Cysteine , Care Excellence , Fast Track Designated , British Columbia , State University , California Institute , Clinical Pharmacology , Clinical Oncology , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் ,

Cinergen: Najib Babul: On the Accuracy of Acute Pain Recall


Cinergen: Najib Babul: On the Accuracy of Acute Pain Recall
CLARK COUNTY, NV / ACCESSWIRE / January 5, 2021 / The accuracy of pain recall has important implications for both clinical trials and clinical management where pain is a prominent or primary outcome measure or symptom. Dr. Najib Babul, an experienced drug development and regulatory affairs consultant discusses the accuracy of remembered pain and the benefits and limitations of relying on patient s memory for pain. His conclusion, as reported in peer-reviewed medical journals is that patient recollection of acute pain is generally quite reliable.
Pain is a major public health problem, resulting in personal suffering, reduced productivity, and increased health care costs. A report from the Institute of Medicine Committee on Advancing Pain Research, Care, and Education states that chronic pain affects approximately 100 million adults in the U.S. and costs the economy over $600 billion annually. This includes $300 bil ....

New York , United States , United Kingdom , New England Baptist Hospital , Mark Jensen , Kostenloser Wertpapierhandel , Jennifer Bolton , University Of Washington , University Of British Columbia , University Of New York , University College In Bournemouth , Shoulder Center , Department Of Rehabilitation Medicine , California Institute Of Advanced Management , Najib Babul , Medicine Committee , Advancing Pain Research , Boston Sports , Vice Chair , Rehabilitation Medicine , Postgraduate Studies , Marta Meana , Nevada Las , British Columbia , State University , California Institute ,